SASadia Afrin

Sadia Afrin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sadia Afrin has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nipah virus as an emerging threat: mutational dynamics, pathogenesis, and advances in vaccine development- a systematic review

    by Sadia Afrin, Rezwan Ahmed Mahedi, Asma Akhter Radia, Joti Devi

    Nipah virus (NiV) is an emerging zoonotic pathogen with significant pandemic potential. Large outbreaks, such as in Malaysia, required the culling of over one million pigs to control transmission. However, the epidemiology of NiV among animal hosts, including pigs, horses, and bats, remains incompletely understood. NiV infection primarily affects the respiratory and nervous systems, causing severe pneumonia, vasculitis, and meningitis, while encephalitis may be mild or infrequent in some cases. This systematic review summarizes current evidence on NiV mutational variation, pathogenesis, treatment strategies, and vaccine development up to 2022. Data were collected from major databases, including PubMed, PMC, and Cochrane Library. Due to limited therapeutic options, NiV management relies mainly on supportive care, as no approved vaccines or specific antiviral treatments are available for humans or livestock. Preventive strategies focus on reducing zoonotic transmission, particularly by minimizing contact between livestock and bat-contaminated food sources, and improving farm management practices. Early detection and continuous surveillance of high-risk populations and animal reservoirs are essential for outbreak control. Current vaccine research targets viral antigens using subunit and vector-based approaches. Overall, further studies are urgently needed to develop effective vaccines and antiviral therapies for NiV infection.

  • Open Access

    Ethnomedicinal Uses, Phytochemical Constituents and Pharmacological Properties of Clerodendrum infortunatum Linn: A Review

    by Rezwan Ahmed Mahedi, Sadia Afrin, Shokhida Rasulova Shukhrat Kizi, Mohammad Chand Jamali, Nikolaos Syrmos, Geldiev Bexruz, Intizor Avazmetova, Jalolbek Doschanov, Kurbanova Khurliman, Doniyor Umarov

    Background: Clerodendrum infortunatum L., a member of the Lamiaceae family, is an important ethnopharmacologically relevant plant that is widely used in the traditional management of infectious, inflammatory, metabolic, and parasitic diseases in South and Southeast Asia. Although this plant is widely used in traditional medicine, scientific evidence is still in an unorganized state. Objective: The purpose of this review is to present consolidated information on ethnomedicinal uses, phytoconstituents, and pharmacological properties of Clerodendrum infortunatum. Methods: Appropriate keywords were used in the search for relevant literature from Google Scholar and PubMed databases regarding the phytochemical, ethnomedicinal, and pharmacological effects of Clerodendrum infortunatum . Results: Ethnomedical research shows that stems, roots, leaves, and flowers can be used as treatments for fever, helminthiasis, wound healing, inflammation, respiratory issues, skin problems, and envenomation. In secondary metabolite studies, research found elements such as flavonoids, phenolic acids, clerodane diterpenoids, phenolic acids, steroids, saponins, fatty acids, and nitrogen compounds. Preclinical research, mostly in vitro and in vivo studies, reports evidence of a wide range of biological activities such as inflammation, anti-infection, anti-helminth, liver protection, anti-diabetic, pain relief, anti-epileptic, wound healing, and anticancer activities. Conclusion: The available evidence is mainly preclinical and has little to no mechanistic explanation, varies in extraction procedures, lacks standardization in plant matter, and has underdeveloped toxicity and pharmacokinetic studies. There are no clinical trials in humans, and some parts of plants, especially the fruits and flowers, are still understudied. Clerodendrum infortunatum is an ethnopharmacologically relevant species with some hopeful preclinical data, but the rigorous phytochemical standardisation, mechanistic study, thorough clinical trial design are critical to prove the potential of this plant in evidence-based therapeutics.

  • Open Access

    Bortezomib in multiple myeloma management

    by Hrishik Iqbal, Mohammad Nazmul Islam, Srikumar Chakravarthi, Mohammad Chand Jamali, Rezwan Ahmed Mahedi, Sadia Afrin, Pujita Roy, Fahadul Alam, Md.SHajalal Reza, Νikolaos Syrmos

    Multiple myeloma (MM) is a hematologic malignancy characterized by the uncontrolled proliferation of plasma cells, leading to complications such as bone lesions, renal dysfunction, and immune suppression. Over the past three decades, its incidence has risen significantly, attributed to factors such as aging populations and improved diagnostic methods. Treatment strategies have evolved considerably, transitioning from alkylating agents and high-dose chemotherapy to targeted therapies, including proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs). Bortezomib, a first-in-class PI, has revolutionized MM management by inhibiting proteasome activity, thereby inducing apoptosis in malignant plasma cells. This review evaluates the efficacy, safety, and clinical applications of bortezomib, both as monotherapy and in combination with dexamethasone, IMiDs, and conventional chemotherapies. Key clinical trials, such as VISTA and SUMMIT, demonstrate its superiority over traditional regimens, improving response rates and survival outcomes. However, its use is associated with adverse effects, including peripheral neuropathy, hematologic toxicities, and gastrointestinal disturbances, necessitating dose modifications and supportive care. Emerging combinations with monoclonal antibodies and novel agents further enhance therapeutic potential, though optimal sequencing remains under investigation. Systematic literature search was performed using PubMed and Cochrane to identify relevant studies on the applications of bortezomib. The search was inclusive of all publications up to May 2025, without restriction by publication year, to ensure a thorough review of research on bortezomib. Studies focusing on multiple myeloma (MM) and the efficacy of bortezomib were prioritized. A broad set of keywords was employed reflecting the diverse applications of bortezomib in MM treatment. The search strategy was designed to capture a wide range of relevant studies. By synthesizing evidence from 77 studies, this review highlights bortezomib’s pivotal role in MM treatment while addressing challenges in toxicity management. Future research should focus on refining combination strategies and minimizing side effects to maximize long-term patient outcomes.